An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy (original) (raw)
Martuza, R. et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science252, 854–858 (1991). ArticleCASPubMed Google Scholar
Bischoff, J. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science274, 373–378 (1996). ArticleCASPubMed Google Scholar
Kucharczuk, J. et al. Use of a “replication-restricted”" herpes virus to treat experimental human malignant mesothelioma. Cancer Res.57, 466–470 (1997). CASPubMed Google Scholar
Carew, J. et al. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum. Gene Ther.10, 1599–1604 (1999). ArticleCASPubMed Google Scholar
Mineta, T. et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med.1, 938–942 (1995). ArticleCASPubMed Google Scholar
Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med.3, 639–645 (1997). ArticleCASPubMed Google Scholar
Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene19, 2–12 (2000). ArticleCASPubMed Google Scholar
Kirn, D. et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol.17, 391a (1998). Google Scholar
Markert, J. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther.7, 1–4 (2000). Article Google Scholar
Whyte, P. et al. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature334, 124–127 (1988). ArticleCASPubMed Google Scholar
Moran, E., Zerler, B., Harison, T. & Mathews, M. Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes. Mol. Cell. Biol.6, 3470–3474 (1986). ArticleCASPubMedPubMed Central Google Scholar
Whyte, P., Ruley, H. & Harlow, E. Two regions of the adenovirus early region 1A proteins are required for transformation. J. Virol.62, 257–261 (1988). CASPubMedPubMed Central Google Scholar
Whyte, P., Williamson, N. & Harlow, E. Cellular targets for transformation by the adenovirus E1A proteins. Cell56, 67–70 (1989). ArticleCASPubMed Google Scholar
Jelsma, T. et al. Sequences in E1A proteins of human adenovirus required for cell transformation, repression of a transcriptional enhancer, and induction of proliferating cell nuclear antigen. Virology171, 120–124 (1989). ArticleCASPubMed Google Scholar
Barbeau, D. et al. Functional interactions within adenovirus E1A protein complexes. Oncogene9, 359–363 (1994). CASPubMed Google Scholar
Hay, J. et al. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum. Gene Ther.10, 579–583 (1999). ArticleCASPubMed Google Scholar
Kirn, D., Hermiston, T. & McCormick, F. ONYX-015: clinical data are encouraging. Nature Med.4, 1341–1345 (1998). ArticleCASPubMed Google Scholar
Rudin, C. et al. Preliminary report: adenovirus ONYX-015 administered by mouthwash as a chemopreventative agent and for the treatment of oral dysplastic lesions. Proc. Am. Soc. Clin. Oncol.18, 1715 (1999). Google Scholar
Kirn, D. et al. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol.18, 1505 (1999). Google Scholar
Khuri, F. et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nature Med.6, 879–885 (2000). ArticleCASPubMed Google Scholar
Hateboer, G. et al. mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect. J. Biol. Chem.271, 25906–25910 (1996). ArticleCASPubMed Google Scholar
Hateboer, G. et al. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev.10, 2960–2965 (1996). ArticleCASPubMed Google Scholar
Dumont, D. & Branton, P. Phosphorylation of adenovirus E1A proteins by the p34cdc2 protein kinase. Virology189, 111–115 (1992). ArticleCASPubMed Google Scholar
Dumont, D., Marcellus, R., Bayley, S. & Branton, P. Role of phosphorylation near the amino terminus of adenovirus type 5 early region 1A proteins. J. Gen. Virol.74, 583–587 (1993). ArticleCASPubMed Google Scholar
Whalen, S., Marcellus, R., Barbeau, D. & Branton, P. Importance of the Ser-132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein. J. Virol.70, 5373–5378 (1996). CASPubMedPubMed Central Google Scholar
Medina, D. et al. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells. Blood94, 3499–3506 (1999). CASPubMed Google Scholar
Yuan, F. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res.55, 3752–3757 (1995). CASPubMed Google Scholar
Barker, D.D. & Berk, A.J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology156, 107–121 (1987). ArticleCASPubMed Google Scholar